SOURCE-LINKED STUDY SUMMARY
Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.
Abstract summarizedQuality not appraised
- What was studied
- A retrospective US study compared tirzepatide and semaglutide for asthma flare-ups in adults with asthma and type 2 diabetes.
- Who / model studied
- After matching, each group included 8176 adults, followed for 12 months. Time to the first asthma flare-up was the primary outcome.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Flare-up rates were similar: 11.0% with tirzepatide versus 11.1% with semaglutide. Secondary analyses linked tirzepatide to less rescue-inhaler use, while systemic corticosteroid use was similar.
- Limitations & context
- The authors call for randomized trials to clarify the role of these medicines in asthma.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.2147/jaa.s637738